Datamonitor’s OTC Pharmaceuticals - Global Group of Eight (G8) Industry Guide is an essential resource for top-level data and analysis covering the OTC Pharmaceuticals industry in each of the G8 (United States, Canada, Germany, France, United Kingdom, Italy, Russia and Japan) countries. The report includes easily comparable data on market value, volume, segmentation and market share, plus full five year market forecasts. It examines future problems, innovations and potential growth areas within the market.
Scope of the Report
* Contains an executive summary and data on value, volume and segmentation
* Provides textual analysis of the industry’s prospects, competitive landscape and profiles of the leading companies
* Incorporates in-depth five forces competitive environment analysis and scorecards
* Compares data from the US, Canada, Germany, France, UK, Italy, Russia and Japan, alongside individual chapters on each country. .
* Includes a five-year forecast of the industry
Highlights
The G8 OTC Pharmaceuticals market grew by 2.7% between 2005 and 2009 to reach a value of $68999.2 billion
In 2014, the market is forecast to have a value of $77727.6 billion, an increase of 2.4% from 2009.
The US is the world’s largest market and generates 39.9% of global revenues in 2009.
Why you should buy this report
* Spot future trends and developments
* Inform your business decisions
* Add weight to presentations and marketing materials
* Save time carrying out entry-level research
Market Definition
The OTC pharmaceuticals market consists of the retail sale of traditional medicines, cough and cold preparations (tablets, mixtures, lozenges, topical remedies, inhalers), vitamins and minerals (multi-vitamins, single minerals, single vitamins, tonics, cod liver oil), indigestion preparations (tablets, powders, mixtures), analgesics (Paracetamol, Ibuprofen, Aspirinand other analgesics), and medicated skin products (anti-bacteria’s, acne treatments, anti-fungal, disinfectants and other), topical OTC medicines (anesthetic products, anti-itch products, antibiotic creams/gels), plasters & bandages (adhesive bandages/plasters, first aid tape, gauze pads/rolled gauze, liquid bandages and other tape or bandage), first aid kits and other (anti-smoking aids, rectal medications, eye/ear drops, sleeping aids, and motion sickness).
ABOUT DATAMONITOR 2
INTRODUCTION 23
What is this report about? 23
Who is the target reader? 23
How to use this report 23
Definitions 23
GROUP OF EIGHT (G8) OTC PHARMACEUTICALS INDUSTRY OUTLOOK 24
OTC PHARMACEUTICALS IN CANADA 31
Market overview 31
Market value 32
Market segmentation I 33
Market segmentation II 34
Market share 35
Five forces analysis 36
Market Forecasts 44
Leading companies 46
Market distribution 61
Macroeconomic indicators 62
OTC PHARMACEUTICALS IN FRANCE 64
Market overview 64
Market value 65
Market segmentation I 66
Market segmentation II 67
Market share 68
Five forces analysis 69
Market Forecasts 77
Leading companies 79
Market distribution 96
Macroeconomic indicators 97
OTC PHARMACEUTICALS IN GERMANY 99
Market overview 99
Market value 100
Market segmentation I 101
Market segmentation II 102
Market share 103
Five forces analysis 104
Market Forecasts 111
Leading companies 113
Market distribution 129
Macroeconomic indicators 130
OTC PHARMACEUTICALS IN ITALY 132
Market overview 132
Market value 133
Market segmentation I 134
Market segmentation II 135
Market share 136
Five forces analysis 137
Market Forecasts 145
Leading companies 147
Market distribution 166
Macroeconomic indicators 167
OTC PHARMACEUTICALS IN JAPAN 169
Market overview 169
Market value 170
Market segmentation I 171
Market segmentation II 172
Market share 173
Five forces analysis 174
Market Forecasts 181
Leading companies 183
Market distribution 197
Macroeconomic indicators 198
OTC PHARMACEUTICALS IN RUSSIA 200
Market overview 200
Market value 201
Market segmentation I 202
Market segmentation II 203
Market share 204
Five forces analysis 205
Market Forecasts 212
Leading companies 214
Market distribution 228
Macroeconomic indicators 229
OTC PHARMACEUTICALS IN THE UNITED KINGDOM 231
Market overview 231
Market value 232
Market segmentation I 233
Market segmentation II 234
Market share 235
Five forces analysis 236
Market Forecasts 244
Leading companies 246
Market distribution 265
Macroeconomic indicators 266
OTC PHARMACEUTICALS IN THE UNITED STATES 268
Market overview 268
Market value 269
Market segmentation I 270
Market segmentation II 271
Market share 272
Five forces analysis 273
Market Forecasts 281
Leading companies 283
Market distribution 299
Macroeconomic indicators 300
APPENDIX 302
Data Research Methodology 302
LIST OF TABLES
Table 1: G8 otc pharmaceuticals industry, revenue($m), 2005–14 25
Table 2: G8 OTC pharmaceuticals industry, revenue by country ($m), 2005–09 28
Table 3: G8 OTC pharmaceuticals industry forecast, revenue by country ($m), 2009–14 30
Table 4: Canada otc pharmaceuticals market value: $ million, 2005–09 32
Table 5: Canada otc pharmaceuticals Market segmentation I:% share, by value, 2009 33
Table 6: Canada otc pharmaceuticals Market segmentation II: % share, by value, 2009 34
Table 7: Canada otc pharmaceuticals market share: % share, by value, 2009 35
Table 8: Canada OTC pharmaceuticals market value forecast: $ million, 2009–14 44
Table 9: Johnson & Johnson: key facts 46
Table 10: Johnson & Johnson: key financials ($) 49
Table 11: Johnson & Johnson: key financial ratios 50
Table 12: GlaxoSmithKline Plc: key facts 52
Table 13: GlaxoSmithKline Plc: key financials ($) 55
Table 14: GlaxoSmithKline Plc: key financials (£) 56
Table 15: GlaxoSmithKline Plc: key financial ratios 56
Table 16: Jamieson Laboratories: key facts 59
Table 17: Canada otc pharmaceuticals market distribution: % share, by value, 2009 61
Table 18: Canada size of population (million), 2005–09 62
Table 19: Canada gdp (constant 2000 prices, $ billion), 2005–09 62
Table 20: Canada gdp (current prices, $ billion), 2005–09 62
Table 21: Canada inflation, 2005–09 63
Table 22: Canada consumer price index (absolute), 2005–09 63
Table 23: Canada exchange rate, 2005–09 63
Table 24: France otc pharmaceuticals market value: $ million, 2005–09 65
Table 25: France otc pharmaceuticals Market segmentation I:% share, by value, 2009 66
Table 26: France otc pharmaceuticals Market segmentation II: % share, by value, 2009 67
Table 27: France otc pharmaceuticals market share: % share, by value, 2009 68
Table 28: France OTC pharmaceuticals market value forecast: $ million, 2009–14 77
Table 29: Procter & Gamble Company, The: key facts 79
Table 30: Procter & Gamble Company, The: key financials ($) 82
Table 31: Procter & Gamble Company, The: key financial ratios 83
Table 32: Sanofi-Aventis: key facts 85
Table 33: Sanofi-Aventis: key financials ($) 87
Table 34: Sanofi-Aventis: key financials (€) 87
Table 35: Sanofi-Aventis: key financial ratios 88
Table 36: Reckitt Benckiser Plc: key facts 90
Table 37: Reckitt Benckiser Plc: key financials ($) 93
Table 38: Reckitt Benckiser Plc: key financials (£) 93
Table 39: Reckitt Benckiser Plc: key financial ratios 93
Table 40: France otc pharmaceuticals market distribution: % share, by value, 2009 96
Table 41: France size of population (million), 2005–09 97
Table 42: France gdp (constant 2000 prices, $ billion), 2005–09 97
Table 43: France gdp (current prices, $ billion), 2005–09 97
Table 44: France inflation, 2005–09 98
Table 45: France consumer price index (absolute), 2005–09 98
Table 46: France exchange rate, 2005–09 98
Table 47: Germany otc pharmaceuticals market value: $ million, 2005–09 100
Table 48: Germany otc pharmaceuticals Market segmentation I:% share, by value, 2009 101
Table 49: Germany otc pharmaceuticals Market segmentation II: % share, by value, 2009 102
Table 50: Germany otc pharmaceuticals market share: % share, by value, 2009 103
Table 51: Germany OTC pharmaceuticals market value forecast: $ million, 2009–14 111
Table 52: Johnson & Johnson: key facts 113
Table 53: Johnson & Johnson: key financials ($) 115
Table 54: Johnson & Johnson: key financial ratios 116
Table 55: Bayer AG: key facts 118
Table 56: Bayer AG: key financials ($) 121
Table 57: Bayer AG: key financials (€) 121
Table 58: Bayer AG: key financial ratios 122
Table 59: GlaxoSmithKline Plc: key facts 124
Table 60: GlaxoSmithKline Plc: key financials ($) 126
Table 61: GlaxoSmithKline Plc: key financials (£) 127
Table 62: GlaxoSmithKline Plc: key financial ratios 127
Table 63: Germany otc pharmaceuticals market distribution: % share, by value, 2009 129
Table 64: Germany size of population (million), 2005–09 130
Table 65: Germany gdp (constant 2000 prices, $ billion), 2005–09 130
Table 66: Germany gdp (current prices, $ billion), 2005–09 130
Table 67: Germany inflation, 2005–09 131
Table 68: Germany consumer price index (absolute), 2005–09 131
Table 69: Germany exchange rate, 2005–09 131
Table 70: Italy otc pharmaceuticals market value: $ million, 2005–09 133
Table 71: Italy otc pharmaceuticals Market segmentation I:% share, by value, 2009 134
Table 72: Italy otc pharmaceuticals Market segmentation II: % share, by value, 2009 135
Table 73: Italy otc pharmaceuticals market share: % share, by value, 2009 136
Table 74: Italy OTC pharmaceuticals market value forecast: $ million, 2009–14 145
Table 75: Bayer AG: key facts 147
Table 76: Bayer AG: key financials ($) 151
Table 77: Bayer AG: key financials (€) 151
Table 78: Bayer AG: key financial ratios 152
Table 79: GlaxoSmithKline Plc: key facts 154
Table 80: GlaxoSmithKline Plc: key financials ($) 158
Table 81: GlaxoSmithKline Plc: key financials (£) 158
Table 82: GlaxoSmithKline Plc: key financial ratios 159
Table 83: Johnson & Johnson: key facts 161
Table 84: Johnson & Johnson: key financials ($) 163
Table 85: Johnson & Johnson: key financial ratios 164
Table 86: Italy otc pharmaceuticals market distribution: % share, by value, 2009 166
Table 87: Italy size of population (million), 2005–09 167
Table 88: Italy gdp (constant 2000 prices, $ billion), 2005–09 167
Table 89: Italy gdp (current prices, $ billion), 2005–09 167
Table 90: Italy inflation, 2005–09 168
Table 91: Italy consumer price index (absolute), 2005–09 168
Table 92: Italy exchange rate, 2005–09 168
Table 93: Japan otc pharmaceuticals market value: $ million, 2005–09 170
Table 94: Japan otc pharmaceuticals Market segmentation I:% share, by value, 2009 171
Table 95: Japan otc pharmaceuticals Market segmentation II: % share, by value, 2009 172
Table 96: Japan otc pharmaceuticals market share: % share, by value, 2009 173
Table 97: Japan OTC pharmaceuticals market value forecast: $ million, 2009–14 181
Table 98: Johnson & Johnson: key facts 183
Table 99: Johnson & Johnson: key financials ($) 186
Table 100: Johnson & Johnson: key financial ratios 187
Table 101: Kracie Holdings, Ltd: key facts 189
Table 102: Novartis AG: key facts 191
Table 103: Novartis AG: key financials ($) 194
Table 104: Novartis AG: key financial ratios 195
Table 105: Japan otc pharmaceuticals market distribution: % share, by value, 2009 197
Table 106: Japan size of population (million), 2005–09 198
Table 107: Japan gdp (constant 2000 prices, $ billion), 2005–09 198
Table 108: Japan gdp (current prices, $ billion), 2005–09 198
Table 109: Japan inflation, 2005–09 199
Table 110: Japan consumer price index (absolute), 2005–09 199
Table 111: Japan exchange rate, 2005–09 199
Table 112: Russia otc pharmaceuticals market value: $ million, 2005–09 201
Table 113: Russia otc pharmaceuticals Market segmentation I:% share, by value, 2009 202
Table 114: Russia otc pharmaceuticals Market segmentation II: % share, by value, 2009 203
Table 115: Russia otc pharmaceuticals market share: % share, by value, 2009 204
Table 116: Russia OTC pharmaceuticals market value forecast: $ million, 2009–14 212
Table 117: Ranbaxy Laboratories Limited: key facts 214
Table 118: Ranbaxy Laboratories Limited: key financials ($) 216
Table 119: Ranbaxy Laboratories Limited: key financials (Rs.) 216
Table 120: Ranbaxy Laboratories Limited: key financial ratios 216
Table 121: Johnson & Johnson: key facts 219
Table 122: Johnson & Johnson: key financials ($) 221
Table 123: Johnson & Johnson: key financial ratios 222
Table 124: Krka: key facts 224
Table 125: Krka: key financials ($) 226
Table 126: Krka: key financials (€) 226
Table 127: Krka: key financial ratios 226
Table 128: Russia otc pharmaceuticals market distribution: % share, by value, 2009 228
Table 129: Russia size of population (million), 2005–09 229
Table 130: Russia gdp (constant 2000 prices, $ billion), 2005–09 229
Table 131: Russia gdp (current prices, $ billion), 2005–09 229
Table 132: Russia inflation, 2005–09 230
Table 133: Russia consumer price index (absolute), 2005–09 230
Table 134: Russia exchange rate, 2005–09 230
Table 135: United Kingdom otc pharmaceuticals market value: $ million, 2005–09 232
Table 136: United Kingdom otc pharmaceuticals Market segmentation I:% share, by value, 2009 233
Table 137: United Kingdom otc pharmaceuticals Market segmentation II: % share, by value, 2009 234
Table 138: United Kingdom otc pharmaceuticals market share: % share, by value, 2009 235
Table 139: United Kingdom OTC pharmaceuticals market value forecast: $ million, 2009–14 244
Table 140: Reckitt Benckiser Plc: key facts 246
Table 141: Reckitt Benckiser Plc: key financials ($) 248
Table 142: Reckitt Benckiser Plc: key financials (£) 249
Table 143: Reckitt Benckiser Plc: key financial ratios 249
Table 144: Johnson & Johnson: key facts 252
Table 145: Johnson & Johnson: key financials ($) 255
Table 146: Johnson & Johnson: key financial ratios 256
Table 147: GlaxoSmithKline Plc: key facts 258
Table 148: GlaxoSmithKline Plc: key financials ($) 261
Table 149: GlaxoSmithKline Plc: key financials (£) 262
Table 150: GlaxoSmithKline Plc: key financial ratios 262
Table 151: United Kingdom otc pharmaceuticals market distribution: % share, by value, 2009 265
Table 152: United Kingdom size of population (million), 2005–09 266
Table 153: United Kingdom gdp (constant 2000 prices, $ billion), 2005–09 266
Table 154: United Kingdom gdp (current prices, $ billion), 2005–09 266
Table 155: United Kingdom inflation, 2005–09 267
Table 156: United Kingdom consumer price index (absolute), 2005–09 267
Table 157: United Kingdom exchange rate, 2005–09 267
Table 158: United States otc pharmaceuticals market value: $ million, 2005–09 269
Table 159: United States otc pharmaceuticals Market segmentation I:% share, by value, 2009 270
Table 160: United States otc pharmaceuticals Market segmentation II: % share, by value, 2009 271
Table 161: United States otc pharmaceuticals market share: % share, by value, 2009 272
Table 162: United States OTC pharmaceuticals market value forecast: $ million, 2009–14 281
Table 163: Johnson & Johnson: key facts 283
Table 164: Johnson & Johnson: key financials ($) 286
Table 165: Johnson & Johnson: key financial ratios 287
Table 166: Pfizer: key facts 289
Table 167: Pfizer: key financials ($) 291
Table 168: Pfizer: key financial ratios 291
Table 169: Procter & Gamble Company, The: key facts 294
Table 170: Procter & Gamble Company, The: key financials ($) 296
Table 171: Procter & Gamble Company, The: key financial ratios 297
Table 172: United States otc pharmaceuticals market distribution: % share, by value, 2009 299
Table 173: United States size of population (million), 2005–09 300
Table 174: United States gdp (constant 2000 prices, $ billion), 2005–09 300
Table 175: United States gdp (current prices, $ billion), 2005–09 300
Table 176: United States inflation, 2005–09 301
Table 177: United States consumer price index (absolute), 2005–09 301
Table 178: United States exchange rate, 2005–09 301
LIST OF FIGURES
Figure 1: G8 otc pharmaceuticals industry, revenue($m), 2005–14 24
Figure 2: G8 OTC Pharmaceuticals industry, revenue by country (%), 2009 26
Figure 3: G8 OTC pharmaceuticals industry, revenue by country ($m), 2005–09 27
Figure 4: G8 OTC pharmaceuticals industry forecast, revenue by country ($m), 2009–14 29
Figure 5: Canada otc pharmaceuticals market value: $ million, 2005–09 32
Figure 6: Canada otc pharmaceuticals Market segmentation I:% share, by value, 2009 33
Figure 7: Canada otc pharmaceuticals Market segmentation II: % share, by value, 2009 34
Figure 8: Canada otc pharmaceuticals market share: % share, by value, 2009 35
Figure 9: Forces driving competition in the otc pharmaceuticals market in Canada, 2009 36
Figure 10: Drivers of buyer power in the otc pharmaceuticals market in Canada, 2009 38
Figure 11: Drivers of supplier power in the otc pharmaceuticals market in Canada, 2009 39
Figure 12: Factors influencing the likelihood of new entrants in the otc pharmaceuticals market in Canada, 2009 40
Figure 13: Factors influencing the threat of substitutes in the otc pharmaceuticals market in Canada, 2009 42
Figure 14: Drivers of degree of rivalry in the otc pharmaceuticals market in Canada, 2009 43
Figure 15: Canada OTC pharmaceuticals market value forecast: $ million, 2009–14 45
Figure 16: Johnson & Johnson: revenues & profitability 50
Figure 17: Johnson & Johnson: assets & liabilities 51
Figure 18: GlaxoSmithKline Plc: revenues & profitability 57
Figure 19: GlaxoSmithKline Plc: assets & liabilities 58
Figure 20: Canada otc pharmaceuticals market distribution: % share, by value, 2009 61
Figure 21: France otc pharmaceuticals market value: $ million, 2005–09 65
Figure 22: France otc pharmaceuticals Market segmentation I:% share, by value, 2009 66
Figure 23: France otc pharmaceuticals Market segmentation II: % share, by value, 2009 67
Figure 24: France otc pharmaceuticals market share: % share, by value, 2009 68
Figure 25: Forces driving competition in the otc pharmaceuticals market in France, 2009 69
Figure 26: Drivers of buyer power in the otc pharmaceuticals market in France, 2009 71
Figure 27: Drivers of supplier power in the otc pharmaceuticals market in France, 2009 72
Figure 28: Factors influencing the likelihood of new entrants in the otc pharmaceuticals market in France, 2009 73
Figure 29: Factors influencing the threat of substitutes in the otc pharmaceuticals market in France, 2009 75
Figure 30: Drivers of degree of rivalry in the otc pharmaceuticals market in France, 2009 76
Figure 31: France OTC pharmaceuticals market value forecast: $ million, 2009–14 78
Figure 32: Procter & Gamble Company, The: revenues & profitability 83
Figure 33: Procter & Gamble Company, The: assets & liabilities 84
Figure 34: Sanofi-Aventis: revenues & profitability 88
Figure 35: Sanofi-Aventis: assets & liabilities 89
Figure 36: Reckitt Benckiser Plc: revenues & profitability 94
Figure 37: Reckitt Benckiser Plc: assets & liabilities 95
Figure 38: France otc pharmaceuticals market distribution: % share, by value, 2009 96
Figure 39: Germany otc pharmaceuticals market value: $ million, 2005–09 100
Figure 40: Germany otc pharmaceuticals Market segmentation I:% share, by value, 2009 101
Figure 41: Germany otc pharmaceuticals Market segmentation II: % share, by value, 2009 102
Figure 42: Germany otc pharmaceuticals market share: % share, by value, 2009 103
Figure 43: Forces driving competition in the otc pharmaceuticals market in Germany, 2009 104
Figure 44: Drivers of buyer power in the otc pharmaceuticals market in Germany, 2009 106
Figure 45: Drivers of supplier power in the otc pharmaceuticals market in Germany, 2009 107
Figure 46: Factors influencing the likelihood of new entrants in the otc pharmaceuticals market in Germany, 2009 108
Figure 47: Factors influencing the threat of substitutes in the otc pharmaceuticals market in Germany, 2009 109
Figure 48: Drivers of degree of rivalry in the otc pharmaceuticals market in Germany, 2009 110
Figure 49: Germany OTC pharmaceuticals market value forecast: $ million, 2009–14 112
Figure 50: Johnson & Johnson: revenues & profitability 116
Figure 51: Johnson & Johnson: assets & liabilities 117
Figure 52: Bayer AG: revenues & profitability 122
Figure 53: Bayer AG: assets & liabilities 123
Figure 54: GlaxoSmithKline Plc: revenues & profitability 128
Figure 55: GlaxoSmithKline Plc: assets & liabilities 128
Figure 56: Germany otc pharmaceuticals market distribution: % share, by value, 2009 129
Figure 57: Italy otc pharmaceuticals market value: $ million, 2005–09 133
Figure 58: Italy otc pharmaceuticals Market segmentation I:% share, by value, 2009 134
Figure 59: Italy otc pharmaceuticals Market segmentation II: % share, by value, 2009 135
Figure 60: Italy otc pharmaceuticals market share: % share, by value, 2009 136
Figure 61: Forces driving competition in the otc pharmaceuticals market in Italy, 2009 137
Figure 62: Drivers of buyer power in the otc pharmaceuticals market in Italy, 2009 139
Figure 63: Drivers of supplier power in the otc pharmaceuticals market in Italy, 2009 140
Figure 64: Factors influencing the likelihood of new entrants in the otc pharmaceuticals market in Italy, 2009 141
Figure 65: Factors influencing the threat of substitutes in the otc pharmaceuticals market in Italy, 2009 143
Figure 66: Drivers of degree of rivalry in the otc pharmaceuticals market in Italy, 2009 144
Figure 67: Italy OTC pharmaceuticals market value forecast: $ million, 2009–14 146
Figure 68: Bayer AG: revenues & profitability 152
Figure 69: Bayer AG: assets & liabilities 153
Figure 70: GlaxoSmithKline Plc: revenues & profitability 159
Figure 71: GlaxoSmithKline Plc: assets & liabilities 160
Figure 72: Johnson & Johnson: revenues & profitability 164
Figure 73: Johnson & Johnson: assets & liabilities 165
Figure 74: Italy otc pharmaceuticals market distribution: % share, by value, 2009 166
Figure 75: Japan otc pharmaceuticals market value: $ million, 2005–09 170
Figure 76: Japan otc pharmaceuticals Market segmentation I:% share, by value, 2009 171
Figure 77: Japan otc pharmaceuticals Market segmentation II: % share, by value, 2009 172
Figure 78: Japan otc pharmaceuticals market share: % share, by value, 2009 173
Figure 79: Forces driving competition in the otc pharmaceuticals market in Japan, 2009 174
Figure 80: Drivers of buyer power in the otc pharmaceuticals market in Japan, 2009 176
Figure 81: Drivers of supplier power in the otc pharmaceuticals market in Japan, 2009 177
Figure 82: Factors influencing the likelihood of new entrants in the otc pharmaceuticals market in Japan, 2009 178
Figure 83: Factors influencing the threat of substitutes in the otc pharmaceuticals market in Japan, 2009 179
Figure 84: Drivers of degree of rivalry in the otc pharmaceuticals market in Japan, 2009 180
Figure 85: Japan OTC pharmaceuticals market value forecast: $ million, 2009–14 182
Figure 86: Johnson & Johnson: revenues & profitability 187
Figure 87: Johnson & Johnson: assets & liabilities 188
Figure 88: Novartis AG: revenues & profitability 195
Figure 89: Novartis AG: assets & liabilities 196
Figure 90: Japan otc pharmaceuticals market distribution: % share, by value, 2009 197
Figure 91: Russia otc pharmaceuticals market value: $ million, 2005–09 201
Figure 92: Russia otc pharmaceuticals Market segmentation I:% share, by value, 2009 202
Figure 93: Russia otc pharmaceuticals Market segmentation II: % share, by value, 2009 203
Figure 94: Russia otc pharmaceuticals market share: % share, by value, 2009 204
Figure 95: Forces driving competition in the otc pharmaceuticals market in Russia, 2009 205
Figure 96: Drivers of buyer power in the otc pharmaceuticals market in Russia, 2009 207
Figure 97: Drivers of supplier power in the otc pharmaceuticals market in Russia, 2009 208
Figure 98: Factors influencing the likelihood of new entrants in the otc pharmaceuticals market in Russia, 2009 209
Figure 99: Factors influencing the threat of substitutes in the otc pharmaceuticals market in Russia, 2009 210
Figure 100: Drivers of degree of rivalry in the otc pharmaceuticals market in Russia, 2009 211
Figure 101: Russia OTC pharmaceuticals market value forecast: $ million, 2009–14 213
Figure 102: Ranbaxy Laboratories Limited: revenues & profitability 217
Figure 103: Ranbaxy Laboratories Limited: assets & liabilities 218
Figure 104: Johnson & Johnson: revenues & profitability 222
Figure 105: Johnson & Johnson: assets & liabilities 223
Figure 106: Krka: revenues & profitability 227
Figure 107: Krka: assets & liabilities 227
Figure 108: Russia otc pharmaceuticals market distribution: % share, by value, 2009 228
Figure 109: United Kingdom otc pharmaceuticals market value: $ million, 2005–09 232
Figure 110: United Kingdom otc pharmaceuticals Market segmentation I:% share, by value, 2009 233
Figure 111: United Kingdom otc pharmaceuticals Market segmentation II: % share, by value, 2009 234
Figure 112: United Kingdom otc pharmaceuticals market share: % share, by value, 2009 235
Figure 113: Forces driving competition in the otc pharmaceuticals market in the United Kingdom, 2009 236
Figure 114: Drivers of buyer power in the otc pharmaceuticals market in the United Kingdom, 2009 238
Figure 115: Drivers of supplier power in the otc pharmaceuticals market in the United Kingdom, 2009 239
Figure 116: Factors influencing the likelihood of new entrants in the otc pharmaceuticals market in the United Kingdom, 2009 240
Figure 117: Factors influencing the threat of substitutes in the otc pharmaceuticals market in the United Kingdom, 2009 242
Figure 118: Drivers of degree of rivalry in the otc pharmaceuticals market in the United Kingdom, 2009 243
Figure 119: United Kingdom OTC pharmaceuticals market value forecast: $ million, 2009–14 245
Figure 120: Reckitt Benckiser Plc: revenues & profitability 250
Figure 121: Reckitt Benckiser Plc: assets & liabilities 251
Figure 122: Johnson & Johnson: revenues & profitability 256
Figure 123: Johnson & Johnson: assets & liabilities 257
Figure 124: GlaxoSmithKline Plc: revenues & profitability 263
Figure 125: GlaxoSmithKline Plc: assets & liabilities 264
Figure 126: United Kingdom otc pharmaceuticals market distribution: % share, by value, 2009 265
Figure 127: United States otc pharmaceuticals market value: $ million, 2005–09 269
Figure 128: United States otc pharmaceuticals Market segmentation I:% share, by value, 2009 270
Figure 129: United States otc pharmaceuticals Market segmentation II: % share, by value, 2009 271
Figure 130: United States otc pharmaceuticals market share: % share, by value, 2009 272
Figure 131: Forces driving competition in the otc pharmaceuticals market in the United States, 2009 273
Figure 132: Drivers of buyer power in the otc pharmaceuticals market in the United States, 2009 275
Figure 133: Drivers of supplier power in the otc pharmaceuticals market in the United States, 2009 276
Figure 134: Factors influencing the likelihood of new entrants in the otc pharmaceuticals market in the United States, 2009 277
Figure 135: Factors influencing the threat of substitutes in the otc pharmaceuticals market in the United States, 2009 279
Figure 136: Drivers of degree of rivalry in the otc pharmaceuticals market in the United States, 2009 280
Figure 137: United States OTC pharmaceuticals market value forecast: $ million, 2009–14 282
Figure 138: Johnson & Johnson: revenues & profitability 287
Figure 139: Johnson & Johnson: assets & liabilities 288
Figure 140: Pfizer: revenues & profitability 292
Figure 141: Pfizer: assets & liabilities 293
Figure 142: Procter & Gamble Company, The: revenues & profitability 297
Figure 143: Procter & Gamble Company, The: assets & liabilities 298
Figure 144: United States otc pharmaceuticals market distribution: % share, by value, 2009 299
GlaxoSmithKline PLC
Jamieson Laboratories
KRKA
Novartis AG
Pfizer Inc,
Procter & Gamble Company
Ranbaxy Laboratories Limited
Reckitt Benckiser PLC
Sanofi-Aventis SA
Wyeth
Zentiva NV
Other selected research from the 'Markets' category:
Attention-Deficit Hyperactivity Disorder Market Forecast
Brazil Biofuel Market Outlook (2007-2010)
Other selected research from the 'Management' category:
The Outlook for eR&D Strategies: Online solutions to declining productivity in pharmaceutical research and development
Optimizing Genomics Asset Management for High ROI - Evaluating Strategies to Support the Bio/Pharma<BR />Value Chain